Lanean...
Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
The rapid growth of COVID-19 cases is causing an increasing death toll and also paralyzing the world economy. De novo drug discovery takes years to move from idea and/or pre-clinic to market, and it is not a short-term solution for the current SARS-CoV-2 pandemic. Drug repurposing is perhaps the onl...
Gorde:
| Argitaratua izan da: | RSC Med Chem |
|---|---|
| Egile Nagusiak: | , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
RSC
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8130630/ https://ncbi.nlm.nih.gov/pubmed/34041486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/d0md00367k |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|